[Syllabus]: BRCA-Related Malignancies

Introduction

This course provides a radiologist-focused overview of BRCA-related cancers, emphasizing the critical role radiologists play in recognizing, diagnosing, and managing BRCA1 and BRCA2 mutation carriers. It covers BRCA genetics and inheritance, the distinct clinicopathologic and imaging features of BRCA-associated breast cancer, the performance of mammography, contrast-enhanced mammography, ultrasound, and MRI in this population, NCCN-based testing and surveillance recommendations, and risk-reduction strategies. It also addresses male breast cancer and the other BRCA-associated malignancies—ovarian/fallopian tube/primary peritoneal, pancreatic, prostate, and colorectal cancers—highlighting the patterns of disease that should prompt a radiologist to suggest genetic testing.

Why BRCA Status Matters: Early Detection in Known Carriers

Patients who know they carry a BRCA mutation can enter early, intensified surveillance, which can detect cancer at a curable stage. Because most carriers are unaware of their status, radiologists who recognize suspicious family and clinical patterns can prompt testing that benefits both the patient and their relatives.

Key Points

• A 30-year-old BRCA and CHEK2 carrier began MRI screening at age 30; baseline MRI showed left lower outer non-mass enhancement, and mammography showed bilateral pleomorphic calcifications. Biopsy confirmed stage 0 bilateral DCIS; after bilateral mastectomies she has been cancer-free for seven years.
• A 35-year-old BRCA1 carrier (tested after her mother's primary peritoneal cancer and a cousin's positive result during a fertility workup) had a 2.3 cm cancer on baseline MRI with no axillary nodal involvement; three years later she has no recurrence and has had her first child.
• If cancer is detected before it becomes invasive, the patient by definition cannot die of the disease.
• Family histories of female and male breast, ovarian, pancreatic, prostate, and colon cancers carry a high probability of an underlying genetic mutation; radiologists can alert referring physicians to order genetic testing.
• Synchronous cancers should trigger consideration of a genetic cause: a 50-year-old with rectal adenocarcinoma had a synchronous invasive breast cancer noted on PET/CT and was subsequently found to be a BRCA1 carrier.

BRCA Genetics, Inheritance, and Prevalence

BRCA1 and BRCA2 are distinct tumor suppressor genes that maintain genomic stability and support DNA repair. Mutations are heterogeneous in their effect, and inheritance patterns mean that relatives of both sexes are at risk.

Key Points

• Most cells with BRCA mutations cannot repair damaged DNA and die; occasional survivors accumulate additional chromosomal abnormalities.
• More than 68,000 BRCA1/BRCA2 mutations have been identified; more than 5,000 are considered critical. Some variants (e.g., near the end of the protein) may not affect function or confer increased risk.
• Mutation location influences both magnitude of risk and which cancers are favored (e.g., breast and ovarian vs. predominantly ovarian); knowing the specific locus helps define risk. The BRCA Exchange is an international database of variants at the nucleotide level.
• Environmental and lifestyle factors (e.g., smoking, obesity) also modify cancer risk.
• Inheritance is germline and autosomal dominant: first-degree relatives of a carrier have a 50% chance of carrying the mutation, regardless of sex.
• BRCA1 is the more common mutation (approximately 1 in 300); BRCA2 occurs in approximately 1 in 800.
• Founder effect: individuals of Ashkenazi Jewish descent have approximately a 1 in 40 chance of carrying a BRCA mutation, usually at one of three founder loci.

Breast Cancer Risk and Age at Presentation

BRCA carriers face markedly elevated lifetime breast cancer risk and present at significantly younger ages than the general population—often before average-risk screening begins.

Key Points

• The American Cancer Society reported over 320,000 breast cancer cases in 2025, approximately 55,000 associated with DCIS, and approximately 42,000 deaths.
• Average lifetime risk is approximately 12%; BRCA1 carriers 60–72%; BRCA2 carriers 55–69%.
• An estimated 5–10% of breast cancers are directly related to BRCA mutations, particularly in young and premenopausal women.
• Ashkenazi Jewish women represent about 2.5% of the US population but approximately 12% of breast cancers and 35% of ovarian cancers.
• Probability that familial breast cancer is BRCA-related: approximately 45% with multiple breast cancer cases; over 90% when the family has both breast and ovarian cancer.
• Mean age at presentation: sporadic 61 years; BRCA1 41 years; BRCA2 47 years. Half of BRCA1 carriers will have developed breast cancer by age 40.
• Risk of breast cancer by age 30 is well under 1% in the general population vs. approximately 3% in BRCA carriers—underscoring the need to identify carriers between ages 25 and 30.

Risk Assessment Guidelines

Formal risk assessment in young adulthood is the gateway to genetic testing and early surveillance.

Key Points

• ACR guidelines call for all women to have a breast cancer risk assessment by age 30; NCCN guidelines recommend risk assessment by age 25.
• Risk assessment is not typically performed under age 18, as it would not change management.
• Average-risk ACR screening recommendations do not apply to BRCA carriers.
• Accessible tools include the National Cancer Institute Breast Cancer Risk Assessment Tool (brief) and the Tyrer-Cuzick model (more extensive family history, more accurate risk estimate); both are available free online.
• Women identified as increased risk should be informed and referred for genetic counseling.

Histopathology and Biology of BRCA-Associated Breast Cancer

BRCA-associated breast cancers differ from sporadic cancers in histology, receptor status, and grade. These differences carry implications for screening, treatment, and genetic testing.

Key Points

• Invasive ductal carcinoma accounts for approximately 80% of cancers in sporadic, BRCA1, and BRCA2 groups.
• Invasive lobular carcinoma is more common in non-carriers.
• Medullary carcinoma is much more common in BRCA1 carriers; patients diagnosed with medullary cancer should be considered for BRCA testing.
• DCIS is rare in BRCA1 carriers, who appear to skip the DCIS stage—making MRI screening critically important.
• BRCA1 cancers are much more likely to be triple-negative, high-grade, and poorly differentiated, with poorer prognosis and fewer targeted therapies; because they are less commonly ER-positive, tamoxifen and aromatase inhibitors tend to be less useful.
• BRCA2 cancers resemble sporadic cancers but develop at younger ages and tend to be bilateral.
• Contralateral breast cancer risk is markedly increased, at diagnosis and over the lifetime.
• Breast implant-associated anaplastic large cell lymphoma is more common in BRCA carriers; reconstruction without implants may be considered.
• Knowing BRCA status after a cancer diagnosis still matters: it may inform the choice of bilateral mastectomy over lumpectomy and prompts counseling on other cancer risks.

Clinical Cases: Interval and Post-Mastectomy Cancers

Aggressive tumor biology and residual breast tissue mean that carriers remain at risk despite surveillance gaps or prior surgery.

Key Points

• A 44-year-old with a palpable inner left breast mass had invasive ductal carcinoma with medullary features; the medullary histology triggered testing, which confirmed BRCA1.
• A 37-year-old BRCA1 carrier who had undergone risk-reducing salpingo-oophorectomy waited 15 months between mammographic screens (in 2013, when MRI was less commonly used) and developed a triple-negative cancer absent on the prior exam. Carriers must adhere to a strict annual schedule.
• A 52-year-old BRCA1 carrier with prior bilateral mastectomies and TRAM flap reconstruction developed a palpable recurrent invasive ductal carcinoma posterior to the reconstruction—beyond the reach of mammography but visible on ultrasound and MRI.
• Mastectomy removes only approximately 80–90% of breast tissue; residual tissue under skin flaps and posteriorly can give rise to new cancer.
• Prophylactic bilateral mastectomy in BRCA1 carriers reduces breast cancer risk by about 90%—from a 60–70% lifetime risk to about 5%—but not to zero.
• BRCA carriers are at increased risk of second primary malignancies, most commonly ovarian cancer and contralateral breast cancer, with colorectal cancer third.

Mammography in BRCA Carriers

Mammography remains the mainstay of screening and the only modality proven to reduce breast cancer mortality, but its sensitivity is substantially lower in BRCA carriers.

Key Points

• All BRCA carriers should undergo annual screening mammography beginning at age 30.
• Sensitivity is approximately 80% in the general population but closer to 30% in BRCA carriers.
• Contributing factors: high interval cancer rates (cancers that become clinically apparent between screens) from aggressive high-grade tumors; younger age with denser breast tissue; architectural distortion and spiculation harder to perceive in dense tissue; and a relative lack of malignant calcifications.
• Tomosynthesis and digital mammography should be used in this population, although they have not been well studied in BRCA carriers.
• The most common mammographic feature of BRCA-associated cancer is a well-defined mass; round or oval circumscribed masses that would suggest fibroadenoma in a non-carrier may represent medullary or high-grade cancer.
• BRCA1 cancers rarely show calcifications, both as DCIS and within invasive cancers; BRCA2 cancers more often contain calcifications, similar to sporadic cancers.
• Example: a 44-year-old with a prior normal mammogram developed a palpable interval cancer; young age at diagnosis prompted testing, which was positive, and she underwent bilateral mastectomies and risk-reducing salpingo-oophorectomy.

Contrast-Enhanced Mammography and Ultrasound

Alternative modalities have roles when MRI is not possible, but BRCA-associated cancers frequently appear benign on ultrasound.

Key Points

• Contrast-enhanced mammography (CEM) is an option for carriers who cannot undergo MRI (e.g., pacemaker); it has not been well studied in BRCA carriers, but early studies show high sensitivity and good specificity.
• On ultrasound, BRCA-associated cancers are often round, circumscribed, and hypoechoic; in one study, 50% of malignancies in eventual BRCA carriers were initially designated benign or indeterminate.
• Screening ultrasound is generally not a good option for BRCA carriers and should be used only when screening MRI and CEM are not possible.
• Dense tissue in young carriers can completely mask cancers on mammography, making supplemental screening important.

Breast MRI Screening

Annual MRI combined with mammography is the recommended surveillance strategy for BRCA carriers, offering high sensitivity and specificity and detection at early stages.

Key Points

• Annual screening MRI is recommended in addition to mammography.
• With annual MRI, 97% of cancers in BRCA carriers were diagnosed at stage 0 or I; in that study, only 9% of cancers were identified at mammography.
• Mammography and MRI are complementary: low-grade DCIS may be seen on mammography but not MRI, and mammographically occult cancers are often seen on MRI.
• Common practice alternates the exams every six months (e.g., mammography in January, MRI in July), which may also interrupt the development of interval cancers.
• Regular MRI screening reduced advanced breast cancers by 70% compared with mammography alone; interval cancer rates are essentially zero with annual MRI plus mammography.
• Effective MRI surveillance allows carriers to retain their breasts if they choose.
• Earlier reports of lower MRI sensitivity for DCIS are no longer believed to apply with modern coils and faster imaging; non-calcified DCIS is almost always missed on mammography.
• Despite proven effectiveness, less than 1% of eligible high-risk US women undergo annual screening breast MRI.

Interpretive Pitfalls: Benign-Appearing Cancers and BI-RADS 3

Because BRCA-associated cancers frequently display benign features across all modalities, standard probably-benign pathways do not apply.

Key Points

• On MRI, cancers may be round with circumscribed margins and homogeneous enhancement.
• There is very little role for BI-RADS 3 in BRCA carriers: given the high pretest probability, any solid mass carries a greater than 2% probability of malignancy.
• Recommend biopsy for any solid mass on mammography, ultrasound, or MRI—including new or baseline enhancing masses—rather than six-month follow-up; the main differential is medullary or grade 3 cancer, which can progress significantly in six months.
• Bilateral calcifications, typically a benign pattern, cannot be assumed benign in BRCA carriers; a BRCA and CHEK2 carrier with left non-mass enhancement on MRI had bilateral suspicious calcifications that proved to be bilateral DCIS.

Metastatic Patterns as Clues to BRCA Status

Patterns of metastatic spread can suggest an underlying BRCA mutation, offering general and non-breast radiologists another opportunity to recommend testing.

Key Points

• Brain metastases occur in about 10% of sporadic breast cancers; a high proportion of BRCA1 carriers metastasize to the brain.
• BRCA1 cancers tend to show fewer bone and more lung metastases; BRCA2 cancers tend not to metastasize to the brain.
• Identifying a carrier with metastatic disease still matters: the diagnosis can be shared with family members, enabling earlier detection in relatives.

NCCN Testing Criteria and Surveillance for Female Carriers

NCCN guidelines provide detailed criteria for genetic testing and management of BRCA carriers.

Key Points

• Testing highlights: breast cancer diagnosed under age 50; triple-negative breast cancer; multiple primary breast cancers (more than one primary in one breast or bilateral); any male breast cancer; additional indications per NCCN.
• Surveillance for BRCA-positive women: clinical breast exam starting at age 25; annual breast MRI from age 25 to 75; annual mammography added beginning at age 30.
• Mammography is deferred before age 30 because sensitivity is low in younger, denser breasts and because of a theoretical risk that radiation could damage DNA in patients unable to repair it.

Breast Cancer Risk Reduction

Beyond early detection, carriers may choose interventions to reduce the risk of developing breast cancer.

Key Points

• Prophylactic mastectomy, particularly before menopause, reduces breast cancer risk by more than 90%.
• Risk-reducing salpingo-oophorectomy (removal of the ovaries before menopause) or tamoxifen reduces breast cancer risk by approximately 50%; these patients still require annual MRI and mammography.
• Options range from surveillance alone, to oophorectomy or tamoxifen with surveillance, to prophylactic mastectomy.

Male Breast Cancer in BRCA Carriers

Male breast cancer is uncommon but strongly associated with genetic mutations, particularly BRCA2.

Key Points

• Men account for about 1% of breast cancer patients; approximately 2,800 US men develop breast cancer each year.
• Lifetime risk is about 0.1% in the general male population vs. about 7% with a BRCA2 mutation.
• Mean age at diagnosis is about 67 in the general population vs. 60 in carriers.
• BRCA-associated male breast cancers otherwise behave like sporadic male cancers; most in BRCA2 carriers are ER-positive, PR-positive, and HER2-negative.
• Imaging resembles cancer in women: round or taller-than-wide, angular margins, hypoechoic, vascular.
• A male breast cancer diagnosis should automatically generate a genetic testing referral. Example: a 68-year-old with prior prostate cancer and a daughter with breast cancer had a high-grade ER-positive IDC with nodal metastasis; he was BRCA2-positive, and his daughter's subsequent positive test led to annual MRI surveillance and counseling on other cancer risks.
• NCCN recommends clinical breast exam beginning at age 35 for male carriers; annual screening mammography is acceptable based on personal preference. Physical exam is relatively sensitive given limited breast tissue, and DCIS is rare in men.

Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian cancer is less common than breast cancer but highly lethal. Evidence from prophylactic surgery in BRCA carriers indicates that most "ovarian" cancers originate in the fallopian tube.

Key Points

• Approximately 21,000 US cases and nearly 13,000 deaths occur annually; ovarian cancer is about tenfold less common than breast cancer, with an average lifetime risk of about 1%.
• Lifetime risk rises to about 60% with BRCA1 and 30% with BRCA2.
• Most BRCA-associated ovarian cancers are high-grade serous adenocarcinomas, compared with about 50% in the general population.
• Sporadic ovarian cancer presents around age 63; in BRCA1 carriers incidence rises in the 30s and 40s, with implications for childbearing and fertility planning. BRCA2-associated disease resembles sporadic disease, diagnosed around age 63.
• Imaging appearance does not differ from sporadic ovarian cancer.
• Studies of prophylactic salpingo-oophorectomy specimens revealed high rates of fallopian tube cancer; most ovarian cancers are now believed to be tubal cancers metastatic to the ovary. Ovarian, fallopian tube, and primary peritoneal cancers are considered one disease.
• Removing the ovaries alone does not address the tubal origin; the fallopian tubes must also be removed. Oophorectomy remains valuable for its approximately 50% breast cancer risk reduction.
• Primary peritoneal serous carcinoma and fallopian tube cancer carry a relative risk of 120 times the general population in BRCA1 carriers.
• All women with serous ovarian, fallopian tube, or primary peritoneal serous carcinoma should undergo BRCA testing.
• BRCA carriers have superior five-year survival after treatment, attributed to greater sensitivity to platinum agents and PARP inhibitors.
• Example: a 60-year-old found to be BRCA2-positive after ovarian/tubal cancer entered annual MRI surveillance; five years later MRI detected a small grade 2 IDC that was successfully treated.

Ovarian Cancer Risk Reduction

No screening strategy has been shown to reduce ovarian cancer mortality, making surgical risk reduction the primary option.

Key Points

• Risk-reducing salpingo-oophorectomy reduces risk by more than 85% when performed at a young enough age, with significant reduction when done before age 40.
• Residual peritoneum always remains, so primary peritoneal cancer can still occur after surgery.
• Surveillance with transvaginal ultrasound and serial CA-125 has never been shown to detect tumors early enough to change outcomes and is not recommended.
• Oral contraceptives reduce ovarian cancer risk by about 50%.
• Prophylactic surgery carries significant psychological and emotional impact for young patients; one staged approach is early salpingectomy with IVF, followed by oophorectomy once childbearing is complete, and later mastectomy.
• Example: a 59-year-old BRCA2 carrier with prior breast cancer who declined tubal removal developed metastatic high-grade serous carcinoma.

Pancreatic Cancer

Pancreatic cancer is not screened for in the general population and is usually incurable when symptomatic; select carriers may benefit from surveillance.

Key Points

• Approximately 67,000 US cases annually with a very high death rate; lifetime risk about 1.5%, rising to 5–10% with BRCA.
• BRCA2 carriers may be advised surveillance depending on family pedigree.
• NCCN surveillance: annual contrast-enhanced MRI, MRCP, or endoscopic ultrasound beginning at age 50.
• Aggressive tumors may still escape surveillance: a 64-year-old man with prior breast cancer had a negative MRI, yet six months later follow-up of a small pancreatic cyst revealed stage IV pancreatic cancer.

Prostate Cancer

BRCA2 in particular confers increased risk of clinically aggressive prostate cancer.

Key Points

• More than 300,000 US cases annually; about 10% of patients die of the disease.
• Risk increases with BRCA1 and particularly with BRCA2.
• BRCA2-associated prostate cancers are more aggressive: high-grade histopathology, higher PSA at diagnosis, greater likelihood of distant and nodal metastasis, and decreased overall survival compared with sporadic disease.
• Example: a 47-year-old known BRCA2 carrier undergoing annual PSA screening had a rising PSA; prostate MRI demonstrated high-grade carcinoma.
• Surveillance: digital rectal exam and annual PSA beginning at age 40, augmented by prostate MRI as indicated.

Colorectal Cancer

BRCA1 carriers, especially women under 50, have elevated colorectal cancer risk.

Key Points

• Approximately 154,000 US cases and about 50,000 deaths annually; lifetime risk about 4.2%; average age at diagnosis about 67.
• Women with BRCA1 under age 50 have a fivefold greater risk; about 1% will have developed colorectal cancer by age 50.
• Adenocarcinoma is the most common subtype; imaging appearance matches sporadic cancer.
• Surveillance: BRCA1-positive women—colonoscopy every 3–5 years beginning at age 40; all BRCA carriers—annual fecal occult blood testing and colonoscopy every 3–5 years beginning at age 45.
• Low-dose aspirin appears effective for risk reduction in BRCA carriers.

Other High-Penetrance Syndromes

Additional, less common high-penetrance syndromes also increase breast cancer risk and should be generally familiar to radiologists.

Key Points

• Different cancer types running through a family, or more than one cancer in an individual, should raise suspicion for a genetic mutation.
• Referral to a geneticist is indicated in these scenarios.

Conclusion

Radiologists are positioned to identify BRCA mutation carriers by recognizing family histories, synchronous and multiple cancers, characteristic histologies, metastatic patterns, and the distinct imaging features of BRCA-associated breast cancer. Because these cancers present early, grow aggressively, and frequently appear benign on mammography, ultrasound, and MRI, carriers require early risk assessment, annual MRI combined with mammography, a low threshold for biopsy, and minimal use of BI-RADS 3. Awareness of the associated ovarian/tubal, pancreatic, prostate, colorectal, and male breast cancer risks—and of NCCN-guided surveillance and risk-reduction options—allows radiologists to improve outcomes for patients and, through cascade testing, for their family members.